21. November 2009 00:32
Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved Geodon® (ziprasidone HCI) Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The approval is based on clinical data demonstrating that Geodon is an effective and generally well-tolerated adjunctive treatment for long-term symptom control in patients with bipolar disorder.
[More]
e509995b-1b4e-4e92-b105-966405d5524b|1|5.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Antipsychotic, Arrhythmia, Bipolar Disorder, Blood Pressure, Dementia, Diabetes, Hyperglycemia, Mental Health, Pfizer, Pharmacology, Psychiatry, Psychosis, Schizophrenia
20. November 2009 23:40
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.
[More]
eb34af81-8141-4574-b270-52cb5d01cd03|0|.0
Posted in: Child Health News | Pharmaceutical News
Tags: Abilify, Antidepressant, Antipsychotic, Autism, Bipolar Disorder, Blood Pressure, Cardiovascular Disease, Cell, Cerebrovascular Disease, Constipation, Creatinine, Dehydration, Dementia, Depression, Diabetes, Diabetes Mellitus, Dystonia, Exercise, Heart Failure, Hyperglycemia, Hypersensitivity, Insomnia, Leukopenia, Lipids, Nausea, Neutropenia, New Drug Application, Obesity, Pediatrics, Pneumonia, Psychosis, Schizophrenia, Speech, Stroke, Tardive Dyskinesia, Urticaria, Vomiting
20. November 2009 00:41
Every year, thousands of youngsters in Ontario experience a mental health crisis, yet the vast majority end up waiting months for psychiatric assessment and treatment because of the severe shortage of these specialists. Now a groundbreaking new program is bridging the gap between kids and care.
[More]
16. November 2009 05:57
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.
[More]
61ba286d-5b3b-4047-95a2-27f2235034f8|0|.0
Posted in: Child Health News | Drug Trial News
Tags: Abdominal Pain, Arteriosclerosis, Bipolar Disorder, Blood Pressure, Cardiovascular Disease, CDC, Depression, Drug Abuse, Glaucoma, Headache, Hypersensitivity, Hyperthyroidism, Insomnia, Nausea, Psychiatry, Psychosis, Stroke, Vomiting
13. November 2009 10:23
A large new study confirms that people with severe mental disorders — such as schizophrenia or other psychotic disorders — are 25 percent to 40 percent more prone to die from heart disease than people without mental illness are.
[More]
0231b490-9ebf-45e9-bd3c-28971edb532c|1|4.0
Posted in: Medical Condition News
Tags: Antipsychotic, Cardiovascular Disease, CDC, Dementia, Diabetes, Exercise, Health Reform, Hospital, Psychiatry, Psychosis, Schizophrenia, Smoking
13. November 2009 04:41
Shire plc, the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.
[More]
0d7781a0-d746-4dd4-9500-ffd869a3587b|0|.0
Posted in: Child Health News | Pharmaceutical News
Tags: Abdominal Pain, Arteriosclerosis, Bipolar Disorder, Blood Pressure, Cardiovascular Disease, CDC, Depression, Drug Abuse, Glaucoma, Headache, Hypersensitivity, Hyperthyroidism, Insomnia, Nausea, Psychiatry, Psychosis, Stroke, Vomiting
11. November 2009 23:26
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the re-launch of FOCUS (http://www.vyvanseFOCUS.com), a free, online patient support program for adults taking once-daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and the only online, branded personalized patient support program providing tips and tools for adults diagnosed with ADHD taking a prescription medication.
[More]
687adcd8-f7fd-4a08-b6cf-0520253d29b7|0|.0
Posted in: Medical Condition News | Healthcare News
Tags: Allergy, Arteriosclerosis, Bipolar Disorder, Blood Pressure, CDC, Depression, Glaucoma, Hyperthyroidism, Pseudoephedrine, Psychiatry, Psychosis
5. November 2009 16:33
The research follows last year’s decision by the UK government to reclassify the drug from class C to class B, partly out of concerns that cannabis, especially the more potent varieties, may increase the risk of schizophrenia in young people. However, the evidence for the relationship between cannabis and schizophrenia or psychosis remains controversial.
[More]
3. November 2009 03:02
Schering-Plough Corporation today reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.
[More]
1a7fbbff-144f-40e7-b2ff-2a96b6917170|1|5.0
Posted in: Drug Trial News | Disease/Infection News
Tags: Anemia, Angina, Angioedema, Anorexia, Anxiety, Arthritis, Blindness, Bone, Bone Marrow, Cancer, Cardiomyopathy, Cell, Cellulitis, Cirrhosis, Contraception, Creatinine, Depression, Dyspnea, Edema, Emphysema, Fibrosis, Gastroenteritis, Gout, Headache, Hepatitis C, Hepatology, Hyperglycemia, Hypersensitivity, Hyperthyroidism, Hypertriglyceridemia, Hypothyroidism, Insomnia, Liver Cancer, Lupus, Nausea, Neuropathy, Neutropenia, Pancreatitis, Peginterferon alfa, Pneumonia, Pregnancy, Psoriasis, Psychosis, Pulmonary Hypertension, Rheumatoid Arthritis, Ribavirin, Ritonavir, Sarcoidosis, Sepsis, Thalassemia, Thrombocytopenia, Thrombosis, Transient Ischemic Attack, Urticaria, Vasculitis, Virus, Vomiting, Weight Loss
31. October 2009 05:07
Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.
[More]
40463d79-5df4-42c1-ad98-f8153d2592f6|0|.0
Posted in: Drug Trial News
Tags: Abdominal Pain, Allergy, Anxiety, Arteriosclerosis, Bipolar Disorder, Blood Pressure, CDC, Constipation, Depression, Glaucoma, Hypersensitivity, Hyperthyroidism, Nausea, Pseudoephedrine, Psychiatry, Psychosis, Vomiting, Weight Loss
31. October 2009 04:30
Inflammatory response of brain cells-as indicated by a molecular imaging technique-could tell researchers more about why certain neurologic disorders, such as migraine headaches and psychosis in schizophrenic patients, occur and provide insight into how to best treat them, according to two studies published in the November issue of the Journal of Nuclear Medicine.
[More]
d0fe0515-e823-4ee3-b1bd-0e8110ca8249|0|.0
Posted in: Device / Technology News | Medical Condition News
Tags: Alzheimer's Disease, Anti-Inflammatory, Brain, Depression, Hippocampus, Migraine, Multiple Sclerosis, Nuclear Medicine, Parkinson's Disease, Psychiatry, Psychosis, Radiology, Schizophrenia
31. October 2009 04:01
Shire plc, the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).
[More]
7a84b2da-d9c0-4b12-ab33-9a1c7a2e2f36|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Allergy, Anorexia, Anxiety, Bipolar Disorder, Blood Pressure, CDC, Depression, Glaucoma, Headache, Insomnia, Nausea, Psychiatry, Psychosis, Stroke, Vomiting
31. October 2009 03:09
Schering-Plough Corp. announced today the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.
[More]
c3fa1d4f-06bd-4b30-80ad-b27272ea5cd9|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Anemia, Angina, Angioedema, Anorexia, Anxiety, Arthritis, Blindness, Bone, Bone Marrow, Cancer, Cardiomyopathy, Cell, Cellulitis, Cirrhosis, Contraception, Creatinine, Depression, Dyspnea, Edema, Emphysema, Fibrosis, Gastroenteritis, Gout, Headache, Hepatitis C, Hyperglycemia, Hypersensitivity, Hyperthyroidism, Hypertriglyceridemia, Hypothyroidism, Insomnia, Lupus, Melanoma, Nausea, Neuropathy, Neutropenia, Oncology, Pancreatitis, Pneumonia, Pregnancy, Psoriasis, Psychosis, Pulmonary Hypertension, Rheumatoid Arthritis, Ribavirin, Sarcoidosis, Sepsis, Thalassemia, Thrombocytopenia, Thrombosis, Transient Ischemic Attack, Urticaria, Vasculitis, Vomiting, Weight Loss
30. October 2009 06:01
Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV(TM) (guanfacine) Extended Release Tablets, Vyvanse®( ) (lisdexamfetamine dimesylate) Capsules CII, and Daytrana®( ) (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.
[More]
90dbfda0-42c4-4824-adbb-9725dc6d8df7|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Abdominal Pain, Allergy, Anxiety, Arteriosclerosis, Bipolar Disorder, Blood Pressure, CDC, Constipation, Depression, Glaucoma, Hypersensitivity, Hyperthyroidism, Nausea, Pseudoephedrine, Psychiatry, Psychosis, Vomiting, Weight Loss
28. October 2009 08:55
Modern functional brain imaging techniques are available to psychiatrists and are promising modern-day 'telescopes' to explore in vivo brain activity. Modern psychiatric neuroimaging suggests that only phenomena that may be seen and mathematically computed throughout the scan are real.
[More] 
Subscribe